Lilly and Thrive Global make the case for GLP-1 support between visits
Rachel Batterham and Arianna Huffington described how treatment can change when patients are ready to accept help. Moderator Betty Pio cited a gap in structured follow-up.
Some patients who declined a dietitian or exercise referral when they started medication returned four weeks later ready to accept it, obesity specialist Dr. Rachel Batterham told a Las Vegas audience Monday. Her example gave clinics a concrete question about how they support patients taking GLP-1 medicines. Who checks back after the prescription, when the patient has had time to see what is changing and may be ready for a different conversation?
Batterham, a senior vice president in international medical affairs for obesity at Eli Lilly and Company, spoke with Thrive Global founder and CEO Arianna Huffington. Betty Pio, a partner at Kearney, moderated the Main Stage discussion. Pio said research conducted by Kearney and Thrive suggested that about 70% of patients taking GLP-1 medicines receive no structured support between visits. She presented it as their estimate. Huffington disclosed at the outset that Thrive Global’s relationship with Lilly was a paid partnership. Lilly makes obesity medications, and Thrive develops behavior-change programs.

Batterham said the readiness she saw in her practice could change within a month. At the first visit a patient might decline the referral. Four weeks later a patient might return asking to move forward. “You have to start where they are,” she said. She described some patients who were already active and needed help with sleep. A patient who was ready to talk about nutrition or movement would have a different starting point.
The first referral and the follow-up serve different purposes. The referral offers an option. A later conversation can address whether that option fits a patient’s priorities or whether something else is getting in the way. Pio said clinicians in the Kearney and Thrive work wanted support helping patients with food and movement and faced limits on what they could cover in an appointment. Those time limits explain why the panel kept returning to the interval between visits. It is where people make most of the choices the care team discusses.
“Health is what happens every day,” Huffington said. Her example was pairing a show she already wanted to watch with time on a treadmill or stationary bike. The point was to attach a behavior to something a person already does, then make it small enough to repeat. She described Thrive’s approach as incremental and warned against trying to change everything at once. “Don’t make it punitive,” she said. She also cited a free collection of recipes with no more than five ingredients as an example of material a clinician could share when a visit leaves little time for detailed meal planning.
Huffington said an AI coaching tool in which Lilly had invested could offer suggestions tied to a person’s routines, such as a walk after a meal. She contrasted reminders like that with broad advice a person may already know. A patient can know what a type of diet entails and still have trouble using it to plan a particular meal. The coach, as she described it, would help make the prompt specific. The panel presented the tool as an example of support and supplied no outcome data comparing it with other forms of follow-up.

Batterham supplied the clinical context for why the interval might matter. She described obesity as a chronic disease and explained that weight loss can be followed by changes in hunger, fullness and cravings. She said sleep, stress, movement and food can affect some of the same systems involved in regulating weight. That was the reasoning behind her emphasis on asking about a particular person’s routine. A conversation about exercise is unlikely to tell a clinician much about what is getting in the way if the patient is already comfortable with their activity and struggling to sleep.
The treatment itself also has to fit the patient, Batterham said. “We need to give patients and their doctors options.” She mentioned differences in what people would prefer to take, including a tablet, an injection or less frequent injections. She said Lilly was working on a portfolio of options and on areas she viewed as under-researched, including menopause. Those were research and development interests, and the session supplied no results from those efforts. The examples made clear that her use of individualization extended to how people take medication as well as how they receive support.
The World Health Organization conditionally recommends that adults living with obesity who are prescribed GLP-1 therapy may also be offered intensive behavioral interventions, including structured nutrition and activity support. It judged the evidence that those additions improve outcomes to be low certainty. The guidance supports considering structured help and leaves open which form will work best for a given patient or program. Pio’s estimate identified a gap in contact. It supplied no evidence that any one coaching product, reminder or resource will close it.

Batterham closed by connecting access with how patients are treated when they seek help. She argued that seeing obesity principally as a matter of personal effort can make it harder for patients to get treatment. Huffington made a related point about how to respond when an attempt at changing a habit does not work. She described changing direction without judging the person for the route they had taken. Both comments turn on how a person is received when they come back for help.
For clinics, the discussion points to choices about who can follow up and what they should ask. A dietitian or exercise referral may be useful when a patient wants it. Someone who initially declines may be more open to discussing a different concern, or may be ready for the original referral after living with treatment for a few weeks. Pio’s concern about appointment time makes the distinction practical. A follow-up service must make it easier for the patient and clinician to return to the question without expecting the whole discussion to fit in the prescribing visit.
Batterham’s example gives practices a way to judge whether they have provided that opportunity. The patient who says no at the first visit still needs a way to say yes later. The panel’s most immediate point was to make that later conversation possible and to ask what changed. It is a more specific test of support than counting how many people received a referral on the day they started treatment.